(S,R,S)-AHPC-C8-NH2

Cat. No.:	HY-133487B
CAS No.:	2341796-79-8
Molecular Formula:	$C_{31}H_{47}N_5O_4S$
Molecular Weight:	585.8
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (170.71 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7071 mL	8.5353 mL	17.0707 mL
5 mM	0.3414 mL	1.7071 mL	3.4141 mL
10 mM	0.1707 mL	0.8535 mL	1.7071 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1[1].

IC_{50} & Target

VHL

In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jian Jin, et al. Serine threonine kinase (akt) degradation / disruption compounds and methods of use. Patent WO2019173516A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA